Brolucizumab: Evidence to date in the treatment of neovascular age-related macular degeneration

Nicolas A. Yannuzzi, K. Bailey Freund

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Age-related macular degeneration (AMD) is a global health concern and the leading cause of vision loss in the developed world. Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment of neovascular AMD, but there are still challenges with delivery of care and treatment burden with currently available medications. Brolucizumab is a single-chain antibody fragment inhibitor of all isoforms of VEGF-A. Its small molecular weight allows for high solubility and tissue penetration. Brolucizumab has most recently been evaluated in 2 parallel phase 3 randomized controlled trials which demonstrated its safety and efficacy in an extended dosing regimen. The present review summarizes the safety, visual and anatomic outcomes, and durability of brolucizumab in the treatment of neovascular AMD and discusses some of the extended dosing regimens explored with currently approved medications and other therapies still under clinical investigation.

Original languageEnglish (US)
Pages (from-to)1323-1329
Number of pages7
JournalClinical Ophthalmology
StatePublished - 2019


  • Brolucizumab
  • Neovascular age-related macular degeneration
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Brolucizumab: Evidence to date in the treatment of neovascular age-related macular degeneration'. Together they form a unique fingerprint.

Cite this